The L-α-Lysophosphatidylinositol/GPR55 System and its potential role in human obesity

Diabetes

Volumn 61, Issue 2, 2012, Pages 281-291

  Moreno Navarrete, José María ^a   Catalán, Victoria ^b   Whyte, Lauren ^c   Díaz Arteaga, Adenis ^d   Vázquez Martínez, Rafael ^a   Rotellar, Fernando ^b   Guzmán, Rocío ^a   Gómez Ambrosi, Javier ^b   Pulido, Marina R ^a   Russell, Wendy R ^e   Imbernón, Mónica ^d   Ross, Ruth A ^c   Malagón, María M ^a   Dieguez, Carlos ^d   Fernández Real, José Manuel ^a   Frühbeck, Gema ^b   Nogueiras, Ruben ^d  

^a Instituto de Salud Carlos III   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e ROWETT RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA LYSOPHOSPHATIDYLINOSITOL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR GPR55; PHOSPHATIDYLINOSITOL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANIMAL CELL; ARTICLE; BLOOD LEVEL; BODY FAT; BODY MASS; BODY WEIGHT; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID STORAGE; LIVER; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3T3-L1 CELLS; ADIPOCYTES; ADULT; ANIMALS; BODY MASS INDEX; CALCIUM; CELL DIFFERENTIATION; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; LINEAR MODELS; LIVER; LYSOPHOSPHOLIPIDS; MALE; MICE; OBESITY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER;

EID: 84856524687     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0649     Document Type: Article

References (52)

1. Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007;132:2103-2115 (Pubitemid 46693755)
2. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301 (Pubitemid 36724371)
3. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180 (Pubitemid 44271774)
4. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100 (Pubitemid 43228239)
5. Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55:3053-3060 (Pubitemid 44923642)
6. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008;51:1356-1367
7. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Front Horm Res 2008;36:135-145
8. Pagotto U, Cervino C, Vicennati V, Marsicano G, Lutz B, Pasquali R. How many sites of action for endocannabinoids to control energy metabolism? Int J Obes (Lond) 2006;30(Suppl. 1):S39-S43
9. Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009;30:156-163
10. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 2007;152:984-986 (Pubitemid 350166047)
11. Petitet F, Donlan M, Michel A. GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 2006;67:252-253
12. Ross RA. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci 2011;32:265-269
13. Okuno T, Yokomizo T. What is the natural ligand of GPR55? J Biochem 2011;149:495-497
14. 2+-activated large-conductance K+ channels in endothelial cells. Pflugers Arch 2011;461:177-189
15. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007;362:928-934 (Pubitemid 47390663)
16. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 2009;23:183-193
17. Whyte LS, Ryberg E, Sims NA, et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 2009;106:16511-16516
18. Oka S, Kimura S, Toshida T, Ota R, Yamashita A, Sugiura T. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 2010;147:671-678
19. Billah MM, Lapetina EG. Formation of lysophosphatidylinositol in platelets stimulated with thrombin or ionophore A23187. J Biol Chem 1982;257: 5196-5200 (Pubitemid 12054840)
20. Kobayashi T, Kishimoto M, Okuyama H. Phospholipases involved in lysophosphatidylinositol metabolism in rat brain. J Lipid Mediat Cell Signal 1996;14:33-37 (Pubitemid 26343334)
21. Choi JW, Lee CW, Chun J. Biological roles of lysophospholipid receptors revealed by genetic null mice: an update. Biochim Biophys Acta 2008;1781: 531-539
22. Sawzdargo M, Nguyen T, Lee DK, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 1999;64:193-198 (Pubitemid 29052470)
23. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-1101 (Pubitemid 350166046)
24. Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008;139:225-236
25. Ginde SR, Geliebter A, Rubiano F, et al. Air displacement plethysmography: validation in overweight and obese subjects. Obes Res 2005;13:1232-1237
26. Genuth S, Alberti KG, Bennett P, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167
27. Catalán V, Gómez-Ambrosi J, Ramirez B, et al. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 2007;17:1464-1474
28. Gómez-Ambrosi J, Salvador J, Rotellar F, et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg 2006;16:262-269
29. Gómez-Ambrosi J, Catalán V, Ramírez B, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007;92:3719-3727 (Pubitemid 47435361)
30. Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13: 1185-1191 (Pubitemid 38917907)
31. Moreno-Navarrete JM, Ortega FJ, Rodríguez-Hermosa JI, et al. OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes 2011;60:168-176
32. Bondarenko A, Waldeck-Weiermair M, Naghdi S, Poteser M, Malli R, Graier WF. GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol 2010;161:308-320
33. Kapur A, Zhao P, Sharir H, et al. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 2009;284:29817-29827
34. Rodríguez A, Gómez-Ambrosi J, Catalán V, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 2009;33:541-552
35. Catalán V, Gómez-Ambrosi J, Rotellar F, et al. Validation of endogenous control genes in human adipose tissue: relevance to obesity and obesity-associated type 2 diabetes mellitus. Horm Metab Res 2007;39:495-500 (Pubitemid 47204192)
36. Velásquez DA, Martínez G, Romero A, et al. The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 2011;60:1177-1185
37. Ma MT, Yeo JF, Farooqui AA, Zhang J, Chen P, Ong WY. Differential effects of lysophospholipids on exocytosis in rat PC12 cells. J Neural Transm 2010;117:301-308
38. Gericke MT, Kosacka J, Koch D, et al. Receptors for NPY and PACAP differ in expression and activity during adipogenesis in the murine 3T3-L1 fibroblast cell line. Br J Pharmacol 2009;157:620-632
39. Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843 (Pubitemid 41401077)
40. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007;152:567-575 (Pubitemid 350041541)
41. Johns DG, Behm DJ, Walker DJ, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 2007;152:825-831 (Pubitemid 350034974)
42. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-914 (Pubitemid 36368998)
43. Löfgren P, Sjölin E, Wåhlen K, Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 2007;92:1555-1559 (Pubitemid 46556439)
44. Henstridge CM, Balenga NA, Schröder R, et al. GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 2010; 160:604-614
45. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 2008;105:2699-2704 (Pubitemid 351520576)
46. Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 2000;905: 242-259 (Pubitemid 30255422)
47. Shen Z, Wu M, Elson P, et al. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol 2001;83:25-30 (Pubitemid 32959875)
48. Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006;38:52-63
49. Shi H, Seeley RJ, Clegg DJ. Sexual differences in the control of energy homeostasis. Front Neuroendocrinol 2009;30:396-404
50. Perica's J, Oliver P, Guitard R, Pico C, Palou A. Sexual dimorphism in age-related changes in UCP2 and leptin gene expression in subcutaneous adipose tissue in humans. J Nutr Biochem 2001;12:444-449
51. Rosenbaum M, Pietrobelli A, Vasselli JR, Heymsfield SB, Leibel RL. Sexual dimorphism in circulating leptin concentrations is not accounted for by differences in adipose tissue distribution. Int J Obes Relat Metab Disord 2001;25:1365-1371 (Pubitemid 32835456)
52. Prasad SS, Garg A, Agarwal AK. Enzymatic activities of the human AGPAT isoform 3 and isoform 5: localization of AGPAT5 to mitochondria. J Lipid Res 2011;52:451-462